Abstract
Plasma harvested from convalescent COVID-19 patients (CCP) has been applied as first-line therapy in the early phase of the SARS-CoV2 pandemic through clinical studies using various protocols. We present data from a cohort of 267 hospitalized, severe COVID-19 patients who received CCP. No transfusion-related complications were reported, indicating the overall safety of CCP therapy. Patients who eventually died from COVID-19 received CCP significantly later (3.95 versus 5.22 days after hospital admission) and had higher interleukin 6 (IL-6) levels (28.9 pg/ml versus 102.5 pg/ml) than those who survived. In addition, CCP-transfusion caused a significant reduction in the overall inflammatory status of the patients regardless of the severity of disease or outcome, as evidenced by decreasing C-reactive protein, IL6 and ferritin levels. We conclude that, CCP-transfusion is a safe and effective supplementary treatment modality for hospitalized COVID-19 patients characterized by better expected outcome if applied as early as possible. We also observed that, IL-6 may be a suitable laboratory parameter for patient selection and monitoring of CCP therapy effectiveness.
Competing Interest Statement
The authors have declared no competing interest.
Clinical Trial
NCT04345679
Funding Statement
This research was funded by the Ministry for Innovation and Technology and the grant numbers are the following: K135757 and 2020-1.1.6-JOVO-2021-00010.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The study was conducted according to the guidelines of the Declaration of Helsinki, and approved by the Hungarian National Ethics Comittee (protocol code 1943-6/2020/EUIG and date of approval: 2020.04.15).
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Footnotes
eszter.fodor{at}orthosera.com, olga.kuten{at}orthoser.com
muller.veronika{at}med.semmelweis-univ.hu
ivanyizs{at}gmail.com
jakab.ferenc{at}pte.hu, fanni4444{at}gmail.com, kemenesi.gabor{at}gmail.com
skazelarpad{at}gmail.com, asarkany1{at}gmail.com
nagy.sandor{at}ovsz.hu, foigazgato{at}ovsz.hu, nacsa.janos{at}ovsz.hu
zsombor.lacza{at}orthosera.com
agnes.madar{at}orthosera.com, mira.abrus{at}tf.hu
tordai.attila{at}med.semmelweis-univ.hu
berki.timea{at}pte.hu
dorottya333{at}gmail.com
Conflicts of Interest: The authors declare no conflict of interest. Zsombor Lacza owns stock in OrthoSera kft, a startup company developing the hyperacute serum technology towards clinical application.
Financial Disclosure statement : All authors declare that there is no financial interests related to the material in the manuscript.
Data Availability
Due to the nature of this research, participants of this study did not agree for their data to be shared publicly, so supporting data is not available
